As demonstrated in the BEGIN clinical trial program

Tresiba® offers proven A1C control1

For your pediatric patients with T1D as young as 1 year of age

Tresiba® provides proven A1C reduction with once-daily dosing

In BEGIN YOUNG (Study J)
Changes in A1C from baseline at Week 26 (primary endpoint)1,3